TABLE 2.
Study and demographical characteristics of included RCTs included in the network meta‐analysis of advanced non‐small cell lung cancer patients treated with immune‐based combination therapies
| Trial | Male (%) | Age (median) |
Non‐squamous cell carcinoma (%) |
Smoker (%) | ECOG 0 (%) | Asia (%) | Liver metastases (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Experiment | Control | Experiment | Control | Experiment | Control | Experiment | Control | Experiment | Control | Experiment | Control | Experiment | Control | |
| IMpower 130 | 266 (59.0) | 134 (58.8) | 64 | 65 | 451 (100) | 228 (100) | 403 (89.4) | 211 (92.5) | 189 (42.0) | 91 (39.9) | 12 (2.7) | 3 (1.3) | 69 (15) | 31 (14) |
| IMpower 131 | 279(81.0) | 278 (82.0) | 65 | 65 | 0 | 0 | 311 (91.0) | 316 (93.0) | 115 (34.0) | 110 (32.0) | 41 (12.0) | 37 (11.0) | 70 (20.4) | 69 (20.3) |
| IMpower 132 | 192 (65.8) | 192 (67.1) | 64 | 63 | 292 (100) | 286(100) | 255 (87.3) | 256 (89.5) | 126 (43.2) | 114 (40.1) | 71 (24.3) | 65 (22.7) | 0 | 0 |
| KEYNOTE 189 | 254 (62.0) | 109 (52.9) | 65 | 63.5 | 410 (100) | 206 (100) | 362 (88.3) | 181 (87.9) | 186 (45.4) | 80 (38.8) | 4 (1.0) | 6 (2.9) | 66 (16.1) | 49 (23.8) |
| KEYNOTE 407 | 220 (79.1) | 235 (83.6) | 65 | 65 | 0 | 0 | 256 (92.1) | 262 (93.2) | 73 (26.3) | 90 (32.0) | 54 (19.4) | 52 (18.5) | 0 | 0 |
| KEYNOTE 021G | 22 (37.0) | 26 (41.0) | 62.5 | 63.2 | 60 (100) | 63 (100) | 45 (75.0) | 54 (86.0) | 24 (40.0) | 29 (46.0) | 5 (8.0) | 5 (8.0) | 0 | 0 |
| CAMEL | 146 (71.2) | 149 (72.0) | 59 | 61 | 205 (100) | 207 (100) | NA | NA | 48 (23.4) | 36 (17.5) | NA | NA | 0 | 0 |
| RATIONALE 304 | 168 (75.3) | 79 (71.2) | 60 | 61 | 223 (100) | 111 (100) | 147 (65.9) | 66 (59.4) | 54 (24.2) | 24 (21.6) | NA | NA | 20 (9.0) | 17 (15.3) |
| RATIONALE 307 | 112 (94.1) | 111 (91.7) | 63 | 62 | 0 | 0 | 107 (89.9) | 98 (81.0) | 22 (18.5) | 32 (26.4) | NA | NA | 15 (12.6) | 14 (11.6) |
| NCT01285609 | 326 (84.0) | 309(85.6) | 64 | 64 | 0 | 0 | 383(98.7) | 317(87.8) | 135(34.8) | 124(34.3) | NA | NA | NA | NA |
| CheckMate 227 Part 1 | 393 (67.4) | 385 (66.0) | 64 | 64 | 419 (71.9) | 421 (72.2) | 497 (85.2) | 499 (85.6) | 204 (35.0) | 191 (32.8) | NA | NA | NA | NA |
| CheckMate 227 Part 2 | 393 (67.4) | 385 (66.0) | 64 | 64 | 419 (71.9) | 421 (72.2) | 497 (85.2) | 499 (85.6) | 204 (35.0) | 191 (32.8) | NA | NA | NA | NA |
| CheckMate 9LA | 252 (70.0) | 252 (70.0) | 65 | 65 | 249 (69.0) | 247 (69.0) | 314 (87.0) | 308 (86.0) | 112 (31.0) | 111 (31.0) | NA | NA | 69 (19) | 86 (24) |
| IMpower150 | 240 (60.0) | 239 (59.8) | 63 | 63 | 400 (100) | 400 (100) | 318 (79.5) | 323 (80.8) | 159 (40.1) | 179 (45.1) | 56 (14.0) | 46 (11.5) | 53 (13.2) | 57 (14.2) |
| TASUKI−52 | 163 (91.1) | 164 (92.1) | 64 | 62 | 179 (100) | 178 (100) | 155 (86.6) | 147 (82.6) | 30 (16.8) | 22 (12.4) | 275 (100) | 275 (100) | NA | NA |
Abbreviation: NA, not available.